Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
CStone Pharmaceuticals (HK:2616)
HKEX:2616
CStone Pharmaceuticals (2616) Stock Price & Analysis
0 Followers
2616 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$0.80 - HK$2.95
Previous CloseHK$1.16
Volume432.00K
Average Volume (3M)1.93M
Market Cap
HK$1.46B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 22, 2024EPS Estimate
-HK$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding1,284,191,212
10 Day Avg. Volume1,783,403
30 Day Avg. Volume1,927,793
Standard Deviation0.15
R-Squared0.04
Alpha0.00254
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CStone Pharmaceuticals News
PremiumCompany Announcements
CStone Pharma Advances Cancer Treatment with Strategic Deal
PremiumCompany Announcements
CStone Pharmaceuticals Announces Secretarial Changes
PremiumCompany Announcements
CStone Pharmaceuticals Shareholders Approve Resolutions
PremiumCompany Announcements
CStone Pharmaceuticals Gains China NMPA ApprovalPremiumCompany Announcements
CStone Pharmaceuticals Unveils Promising CS5001 Data
PremiumCompany Announcements
CStone’s Sugemalimab Poised for European Approval
PremiumCompany Announcements
CStone Forms Strategic European Partnership for Cancer Drug
PremiumCompany Announcements
CStone Pharmaceuticals Sets Date for AGMOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
1.13% Mutual Funds
0.61% Other Institutional Investors
98.26% Public Companies and
Individual Investors
2616 FAQ
What was CStone Pharmaceuticals’s price range in the past 12 months?
CStone Pharmaceuticals lowest stock price was HK$0.80 and its highest was HK$2.95 in the past 12 months.
What is CStone Pharmaceuticals’s market cap?
Currently, no data Available
When is CStone Pharmaceuticals’s upcoming earnings report date?
CStone Pharmaceuticals’s upcoming earnings report date is Aug 22, 2024 which is in 48 days.
How were CStone Pharmaceuticals’s earnings last quarter?
CStone Pharmaceuticals released its earnings results on Mar 27, 2024. The company reported -HK$0.14 earnings per share for the quarter, missing the consensus estimate of -HK$0.107 by -HK$0.032.
Is CStone Pharmaceuticals overvalued?
According to Wall Street analysts CStone Pharmaceuticals’s price is currently Overvalued.
Does CStone Pharmaceuticals pay dividends?
CStone Pharmaceuticals does not currently pay dividends.
What is CStone Pharmaceuticals’s EPS estimate?
CStone Pharmaceuticals’s EPS estimate is -HK$0.11.
How many shares outstanding does CStone Pharmaceuticals have?
CStone Pharmaceuticals has 1,284,191,200 shares outstanding.
What happened to CStone Pharmaceuticals’s price movement after its last earnings report?
CStone Pharmaceuticals reported an EPS of -HK$0.14 in its last earnings report, missing expectations of -HK$0.107. Following the earnings report the stock price went up 1.053%.
Which hedge fund is a major shareholder of CStone Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2616
---
CStone Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.02%
12-Months-Change
Fundamentals
Return on Equity
-80.86%
Trailing 12-Months
Asset Growth
-0.52%
Trailing 12-Months
Company Description
CStone Pharmaceuticals
CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.
---
2616 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Guan Chao Holdings Limited
―
Jinke Smart Services Group Co., Ltd. Class H
―
Dragon Rise Group Holdings Ltd.
―
Ascletis Pharma, Inc.
―
---